951. Causes of in-hospital and post discharge mortality among patients hospitalized with laboratory-confirmed influenza, Influenza Hospitalization Surveillance Network, 2014-15.
Session: Oral Abstract Session: Public Health Potpourri
Friday, October 6, 2017: 8:45 AM
Room: 07AB
Background:

Influenza results in an estimated 12,000–56,000 deaths annually in the United States. While in-hospital deaths are well characterized, less is known about deaths that occur after discharge among those hospitalized with influenza.

Methods:

We identified patients hospitalized with laboratory-confirmed influenza who died during hospitalization or within 30 days after discharge during the 2014-15 influenza season for 11 Influenza Hospitalization Surveillance Network sites. We matched cases to the National Center for Health Statistics Electronic Death Registration System and abstracted cause and location of death from death certificates. We compared clinical characteristics between those who died during hospitalization and those who died after hospital discharge using χ2 tests.

Results:

Among 795 patients with laboratory-confirmed influenza who died, 370 (47%) died during hospitalization and 425 (53%) died within 30 days after discharge. Eighteen (2%) were 0-17 years and 652 (82%) were ≥65 years. Common causes of death listed in any position on the death certificate included influenza (35%), other respiratory causes (50%), cardiovascular disease (37%) and sepsis (15%). Among those who died after discharge, 207 (49%) died within 7 days, 86 (20%) within 8-14 days, and 132 (31%) within 15-30 days post discharge. Patients who died after discharge were more likely to be ≥65 years (88 vs 74%) or admitted from a nursing home (48 vs 36%), but were less likely to be admitted to an intensive care unit (30 vs 68%) or receive a pneumonia diagnosis (46 vs 62%) than patients who died during hospitalization (all p <0.001). There were no significant differences in sex, race, underlying conditions, vaccination rates, or time from symptom onset to hospitalization. Patients who died in hospital were more likely to have influenza listed as a cause of death (55 vs 21%, p <0.01).

Conclusion:

Over half of deaths among patients hospitalized with laboratory-confirmed influenza occurred after discharge. Patients who died after discharge were older and less likely to have influenza listed as a cause of death. Deaths that occur after an influenza-related hospitalization represent an important and under-characterized contribution to the burden of seasonal influenza.

Craig McGowan, MS1, Carmen Arriola, DVM, PhD1, Charisse Nitura Cummings, MPH1, Pam D. Kirley, MPH2, Lisa Miller, MD3, James I. Meek, MPH4, Evan J. Anderson, MD5, Maya Monroe, MPH6, Susan Bohm, MS7, Melissa McMahon, MPH8, Marisa Bargsten, MPH9, Shelley Zansky, PhD10, Nancy Bennett, MD, MS11, Krista Lung, MPH12, Ann Thomas, MD, MPH13, William Schaffner, MD, FIDSA, FSHEA14, Andrea Price, LPN15, Sandra Dos Santos Chaves, MD1, Carrie Reed, PhD1 and Shikha Garg, MD, MPH1, (1)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (2)California Emerging Infections Program, Oakland, CA, (3)Colorado Department of Public Health and Environment, Denver, CO, (4)Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, (5)Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA, (6)Maryland Department of Health and Mental Hygiene, Baltimore, MD, (7)Michigan Department of Health and Human Services, Lansing, MI, (8)Minnesota Department of Health, St. Paul, MN, (9)New Mexico Department of Health, Santa Fe, NM, (10)Emerging Infections Program, New York State Department of Health, Albany, NY, (11)University of Rochester Medical Center, Rochester, NY, (12)Bureau of Infectious Diseases, Ohio Department of Health, Columbus, OH, (13)Oregon Public Health Division, Portland, OR, (14)Vanderbilt University School of Medicine, Nashville, TN, (15)Salt Lake County Health Department, Salt Lake City, UT

Disclosures:

C. McGowan, None

C. Arriola, None

C. Nitura Cummings, None

P. D. Kirley, None

L. Miller, None

J. I. Meek, None

E. J. Anderson, AbbVie: Consultant , Consulting fee
NovaVax: Research Contractor , Research support
Regeneron: Research Contractor , Research grant
MedImmune: Research Contractor , Research grant and Research support

M. Monroe, None

S. Bohm, None

M. McMahon, None

M. Bargsten, None

S. Zansky, None

N. Bennett, None

K. Lung, None

A. Thomas, None

W. Schaffner, Pfizer: Scientific Advisor , Consulting fee
Merck: Scientific Advisor , Consulting fee
Novavax: Consultant , Consulting fee
Dynavax: Consultant , Consulting fee
Sanofi-pasteur: Consultant , Consulting fee
GSK: Consultant , Consulting fee
Seqirus: Consultant , Consulting fee

A. Price, None

S. Dos Santos Chaves, None

C. Reed, None

S. Garg, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.